Pharmacogenetics and immunosuppressive drugs

References

• Rosso Felipe C, de Sandes TV, Sampaio EL, et al. Clinical impact of polymorphisms of transport proteins and. enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc 2009;41(5):1441-55
   PubMed Web of Science ®Google Scholar
• de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. Clin Pharmacol Ther 2011;90(3):414-22
   PubMed Web of Science ®Google Scholar
• Fredericks S, Holt DW. Pharmacogenomics of immunosuppressive drug metabolism. Curr Opin Nephrol Hypertens 2003;12(6):607-13
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Bouamar R, van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010;32(4):387-93
   PubMed Web of Science ®Google Scholar
• Wang J. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Rev Mol Diagn 2009;9(4):383-90
   PubMed Web of Science ®Google Scholar
• Elens L, Bouamar R, Shuker N, et al. Clinical implementation of pharmacogenetics in kidney transplantation: CNIs in the starting blocks. Br J Clin Pharmacol 2014;77(4):715-28
   PubMed Web of Science ®Google Scholar
• Tang HL, Ma LL, Xie HG, et al. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. Pharmacogenet Genomics 2010;20(9):525-31
   PubMed Web of Science ®Google Scholar
• Li DY, Teng RC, Zhu HJ, Fang Y. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. Int J Clin Pharmacol Ther 2013;51(6):466-74
   PubMed Web of Science ®Google Scholar
• Crettol S, Venetz JP, Fontana M, et al. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. Ther Drug Monit 2008;30(6):689-99
   PubMed Web of Science ®Google Scholar
• Elens L, van Schaik RH, Panin N, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011;12(10):1383-96
   PubMed Web of Science ®Google Scholar
• Moes DJ, Swen JJ, den Hartigh J, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. CPT Pharmacometrics Syst Pharmacol 2014;3:e100
   PubMedGoogle Scholar
• Elens L, Hesselink DA, Bouamar R, et al. Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. Ther Drug Monit 2014;36(1):71-9
   PubMed Web of Science ®Google Scholar
• Jiang ZP, Wang YR, Xu P, et al. Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin Pharmacol Toxicol 2008;103(5):433-44
   PubMed Web of Science ®Google Scholar
• de Luna CJ, Herrero Cervera MJ, Sánchez Lázaro I, et al. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels. Transplant Proc 2011;43:2241-3
   PubMed Web of Science ®Google Scholar
• Buendia JA, Bramuglia G, Staatz CE. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis. Ther Drug Monit 2014;36(4):442-7
   PubMed Web of Science ®Google Scholar
• Tang HL, Xie HG, Yao Y, Hu YF. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics 2011;21(11):713-20
   PubMed Web of Science ®Google Scholar
• Tanaka K, Terao C, Ohmura K, et al. Significant association between CYP3A5 polymorphism and blood concentration of tacrolimus in patients with connective tissue diseases. J Hum Genet 2014;59(2):107-9
   PubMed Web of Science ®Google Scholar
• Thervet E, Loriot MA, Barbier S, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 2010;87(6):721-6
   PubMed Web of Science ®Google Scholar
• Singh R, Srivastava A, Kapoor R, et al. Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 2009;380(2):169-77
   PubMed Web of Science ®Google Scholar
• Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003;74(3):245-54
   PubMed Web of Science ®Google Scholar
• Kuypers DR, de Jonge H, Naesens M, et al.3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007;82(6):711-25
   PubMed Web of Science ®Google Scholar
• Tavira B, Coto E, Diaz-Corte C, et al. A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients. Pharmacogenet Genomics 2013;23(8):445-8
   PubMed Web of Science ®Google Scholar
• Zuo XC, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics 2013;23(5):251-61
   PubMed Web of Science ®Google Scholar
• Uesugi M, Hosokawa M, Shinke H, et al. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biol Pharm Bull 2013;36(11):1814-21
   PubMed Web of Science ®Google Scholar
• Shi XJ, Geng F, Jiao Z, et al. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. J Clin Pharm Ther 2011;36(5):614-24
   PubMed Web of Science ®Google Scholar
• Li Y, Hu X, Cai B, et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transpl Immunol 2012;27(1):12-18
   PubMed Web of Science ®Google Scholar
• Provenzani A, Notarbartolo M, Labbozzetta M, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med 2011;28(6):1093-102
   PubMed Web of Science ®Google Scholar
• Li D, Lu W, Zhu JY, et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 2007;32(5):505-15
   PubMed Web of Science ®Google Scholar
• Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005;5(3):595-603
   PubMed Web of Science ®Google Scholar
• Llaudo I, Colom H, Gimenez-Bonafe P, et al. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transpl Int 2013;26(2):177-86
   PubMed Web of Science ®Google Scholar
• Sam WJ, Chamberlain CE, Lee SJ, et al. Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients. Transplantation 2011;92(12):1342-7
   PubMed Web of Science ®Google Scholar
• Lemaitre F, Bezian E, Goldwirt L, et al. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit 2012;34(6):686-94
   PubMed Web of Science ®Google Scholar
• Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation. Clin Transplant 2011;25(1):146-50
   PubMed Web of Science ®Google Scholar
• Fujiyama N, Miura M, Satoh S, et al. Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Xenobiotica 2009;39(5):407-14
   PubMed Web of Science ®Google Scholar
• Guo D, Pang LF, Han Y, et al. Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol 2013;69(4):843-9
   PubMed Web of Science ®Google Scholar
• Frymoyer A, Verotta D, Jacobson P, Long-Boyle J. Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. Br J Clin Pharmacol 2013;75(2):463-75
   PubMed Web of Science ®Google Scholar
• Sanchez-Fructuoso AI, Maestro ML, Calvo N, et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant Proc 2009;41(6):2313-16
   PubMed Web of Science ®Google Scholar
• van Schaik RH, van Agteren M, de Fijter JW, et al. UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients. Clin Pharmacol Ther 2009;86(3):319-27
   PubMed Web of Science ®Google Scholar
• Yang JW, Lee PH, Hutchinson IV, et al. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid. Ther Drug Monit 2009;31(5):542-8
   PubMed Web of Science ®Google Scholar
• Woillard JB, Rerolle JP, Picard N, et al. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele. Br J Clin Pharmacol 2010;69(6):675-83
   PubMed Web of Science ®Google Scholar
• Ting LS, Benoit-Biancamano MO, Bernard O, et al. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Pharmacotherapy 2010;30(11):1097-108
   PubMed Web of Science ®Google Scholar
• Miura M, Kagaya H, Satoh S, et al. Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit 2008;30(5):559-64
   PubMed Web of Science ®Google Scholar
• Lloberas N, Torras J, Cruzado JM, et al. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study. Nephrol Dial Transplant 2011;26(11):3784-93
   PubMed Web of Science ®Google Scholar
• Geng F, Jiao Z, Dao YJ, et al. The association of the UGT1A8, SLCO1B3 and ABCC2/ABCG2 genetic polymorphisms with the pharmacokinetics of mycophenolic acid and its phenolic glucuronide metabolite in Chinese individuals. Clin Chim Acta 2012;413(7-8):683-90
   PubMed Web of Science ®Google Scholar
• Wang J, Figurski M, Shaw LM, Burckart GJ. The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice. Transpl Immunol 2008;19(3-4):192-6
   PubMed Web of Science ®Google Scholar
• Bouamar R, Hesselink DA, van Schaik RH, et al. Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet Genomics 2012;22(6):399-407
   PubMed Web of Science ®Google Scholar
• Michelon H, Konig J, Durrbach A, et al. SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 2010;11(12):1703-13
   PubMed Web of Science ®Google Scholar
• Vlaming ML, van Esch A, Pala Z, et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 2009;8(12):3350-9
   PubMed Web of Science ®Google Scholar
• de Rotte MC, Bulatovic M, Heijstek MW, et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol 2012;39(10):2032-40
   PubMed Web of Science ®Google Scholar
• Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008;9(4):439-51
   PubMed Web of Science ®Google Scholar
• van de Steeg E, van der Kruijssen CM, Wagenaar E, et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos 2009;37(2):277-81
   PubMed Web of Science ®Google Scholar
• Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009;27(35):5972-8
   PubMed Web of Science ®Google Scholar
• Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011;57(4):612-19
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Bruun GH, Yang W, et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res 2012;22(1):1-8
   PubMed Web of Science ®Google Scholar
• Ramsey LB, Panetta JC, Smith C, et al. Genome-wide study of methotrexate clearance replicates SLCO1B1. Blood 2013;121(6):898-904
   PubMed Web of Science ®Google Scholar
• Kurzawski M, Dziewanowski K, Lener A, Drozdzik M. TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol 2009;65(5):533-40
   PubMed Web of Science ®Google Scholar
• Lennard L. Implementation of TPMT testing. Br J Clin Pharmacol 2014;77(4):704-14
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58(3):521-90
   PubMed Web of Science ®Google Scholar
• Liang JJ, Geske JR, Boilson BA, et al. TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. Pharmacogenet Genomics 2013;23(12):658-65
   PubMed Web of Science ®Google Scholar
• Smith MA, Marinaki AM, Arenas M, et al. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther 2009;30(4):375-84
   PubMed Web of Science ®Google Scholar
• Kurzawski M, Dziewanowski K, Safranow K, Drozdzik M. Polymorphism of genes involved in purine metabolism (XDH, AOX1, MOCOS) in kidney transplant recipients receiving azathioprine. Ther Drug Monit 2012;34(3):266-74
   PubMed Web of Science ®Google Scholar
• Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41(6):421-30
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Nguyen HT, Vaz AD, et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 2003;31(10):1240-50
   PubMed Web of Science ®Google Scholar
• Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008;64(9):871-6
   PubMed Web of Science ®Google Scholar
• Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur J Clin Pharmacol 2011;67(2):129-34
   PubMed Web of Science ®Google Scholar
• Potts J, Yogaratnam D. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. Ann Pharmacother 2013;47(3):361-7
   PubMed Web of Science ®Google Scholar
• EMA. CHMP assessment report. Esbriet CHMP; London, UK: 2010
   Google Scholar
• Picard N, Marquet P. The influence of pharmacogenetics and cofactors on clinical outcomes in kidney transplantation. Expert Opin Drug Metab Toxicol 2011;7(6):731-43
   PubMed Web of Science ®Google Scholar
• Moscoso-Solorzano GT, Ortega F, Rodriguez I, et al. A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients. Clin Transplant 2008;22(6):722-9
   PubMed Web of Science ®Google Scholar
• Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003;2(3):222-32
   PubMed Web of Science ®Google Scholar
• Woillard JB, Kamar N, Rousseau A, et al. Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients. Pharmacogenet Genomics 2012;22(10):725-32
   PubMed Web of Science ®Google Scholar
• Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics 2010;11(3):369-90
   PubMed Web of Science ®Google Scholar
• Derijks LJ, Wong DR. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr Pharm Des 2010;16(2):145-54
   PubMed Web of Science ®Google Scholar
• Pawlik A, Herczynska M, Kurzawski M, et al. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2009;10(2):303-9
   PubMed Web of Science ®Google Scholar
• Grabar PB, Rozman B, Logar D, et al. Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68(8):1367-8
   PubMed Web of Science ®Google Scholar
• O’Doherty C, Schnabl M, Spargo L, et al. Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics 2012;13(12):1427-34
   PubMed Web of Science ®Google Scholar
• Kooloos WM, Huizinga TW, Guchelaar HJ, Wessels JA. Pharmacogenetics in treatment of rheumatoid arthritis. Curr Pharm Des 2010;16(2):164-75
   PubMed Web of Science ®Google Scholar
• Hinks A, Moncrieffe H, Martin P, et al. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis 2011;70(8):1395-400
   PubMed Web of Science ®Google Scholar
• Yu S, Wu L, Jin J, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 2006;81(1):46-51
   PubMed Web of Science ®Google Scholar
• Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006;12(5):775-80
   PubMed Web of Science ®Google Scholar
• Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 2010;49(3):141-75
   PubMed Web of Science ®Google Scholar
• Gomez-Bravo MA, Salcedo M, Fondevila C, et al. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. J Clin Pharmacol 2013;53(11):1146-54
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang Z, Fan J, et al. Impact of interleukin-10 gene polymorphisms on tacrolimus dosing requirements in Chinese liver transplant patients during the early posttransplantation period. Eur J Clin Pharmacol 2011;67(8):803-13
   PubMed Web of Science ®Google Scholar
• Xue F, Han L, Chen Y, et al. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients. Pediatr Transplant 2014;18(2):166-76
   PubMed Web of Science ®Google Scholar
• Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005;16(5):1501-11
   PubMed Web of Science ®Google Scholar
• Woillard JB, Rerolle JP, Picard N, et al. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther 2010;88(1):95-100
   PubMed Web of Science ®Google Scholar
• Min DI, Ellingrod VL. Association of the CYP3A4*1B 5'-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2003;25(3):305-9
   PubMed Web of Science ®Google Scholar
• Qiu XY, Jiao Z, Zhang M, et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008;64(11):1069-84
   PubMed Web of Science ®Google Scholar
• Kurzawski M, Dabrowska J, Dziewanowski K, Domanski L, Peruzynska M, Drozdzik M. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics 2014;15(2):179-88
   PubMed Web of Science ®Google Scholar
• Malik F, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis: a status report. Pharmacogenomics 2013;14(3):305-14
   PubMed Web of Science ®Google Scholar